The Year in Biotech and What’s Ahead in 2023
The Bio Report
00:00
Gene Therapy for Beta Thalassemia
The FDA did approve three gene therapies in 2022. Two from Bluebird and one from CSL bearing. There are more coming behind that. What's it going to take for these advanced therapies to be market successes? Right. You know, we're talking about two, three million dollars per treatment.
Transcript
Play full episode
